Lyell Immunopharma announced new clinical data Tuesday from a Phase I/II trial of its dual-targeted CD19/CD20 CAR T-cell therapy for relapsed or refractory large B-cell lymphoma. The company ...

Some cancers and chronic inflammatory diseases are treated with immunotherapies. These stimulate the patient's immune system ...

Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to ...

Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer ...

Analysis revealed that patients with T-cell exhausted archetype tumors had significantly higher rates of progressive disease ...